Abeona Therapeutics (NASDAQ:ABEO) Releases Earnings Results, Beats Estimates By $0.03 EPS

Abeona Therapeutics (NASDAQ:ABEO) issued its earnings results on Wednesday. The biopharmaceutical company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.03, FiscalAI reports. The firm had revenue of $8.72 million during the quarter, compared to analyst estimates of $4.57 million.

Here are the key takeaways from Abeona Therapeutics’ conference call:

• ZEVASKYN launch momentum is building, with Abeona treating 5 commercial patients to date, activating 6 qualified treatment centers, and reporting $8.7 million in Q1 2026 net product revenue.
• Management said payer coverage is broadening, with published policies now covering 95% of commercially insured lives and no final payer denials or patient attrition reported so far.
• The company highlighted a deepening patient pipeline, including more than 100 identified patients across centers and the community, plus 45 active referral physicians and several biopsies scheduled this quarter.
• Abeona announced an in-licensed PSMA CAR-T asset for advanced prostate cancer, paid a $7 million upfront fee, and expects first-in-human studies to begin in the second half of 2027 after a June 2026 pre-IND meeting.
• Management said the balance sheet remains strong with $168.3 million in cash and short-term investments, and reiterated expectations for near-term profitability depending on biopsy and treatment cadence.

Abeona Therapeutics Price Performance

Shares of ABEO stock traded up $0.05 during trading hours on Wednesday, hitting $5.73. 2,163,360 shares of the company’s stock were exchanged, compared to its average volume of 1,203,463. The stock’s 50-day moving average is $5.05 and its 200-day moving average is $5.04. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.93 and a quick ratio of 6.74. The stock has a market cap of $325.64 million, a price-to-earnings ratio of 5.56 and a beta of 1.35. Abeona Therapeutics has a 52 week low of $4.00 and a 52 week high of $7.54.

Analysts Set New Price Targets

ABEO has been the subject of a number of recent research reports. Weiss Ratings restated a “sell (d+)” rating on shares of Abeona Therapeutics in a research note on Wednesday, January 21st. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Abeona Therapeutics in a research report on Thursday, March 19th. Oppenheimer reiterated an “outperform” rating on shares of Abeona Therapeutics in a research report on Monday, March 9th. Finally, Stifel Nicolaus set a $17.00 price target on Abeona Therapeutics in a research report on Tuesday, March 17th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.00.

Insider Activity at Abeona Therapeutics

In related news, insider Madhav Vasanthavada sold 5,548 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $5.96, for a total value of $33,066.08. Following the transaction, the insider owned 313,071 shares in the company, valued at $1,865,903.16. This trade represents a 1.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 5.40% of the company’s stock.

Hedge Funds Weigh In On Abeona Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. XTX Topco Ltd boosted its holdings in Abeona Therapeutics by 25.4% in the fourth quarter. XTX Topco Ltd now owns 49,338 shares of the biopharmaceutical company’s stock valued at $260,000 after acquiring an additional 9,979 shares during the last quarter. Tang Capital Management LLC bought a new position in Abeona Therapeutics in the fourth quarter valued at about $5,270,000. Balyasny Asset Management L.P. bought a new position in Abeona Therapeutics in the fourth quarter valued at about $3,118,000. J. Goldman & Co LP bought a new position in Abeona Therapeutics in the fourth quarter valued at about $2,102,000. Finally, AQR Capital Management LLC boosted its holdings in Abeona Therapeutics by 240.7% in the fourth quarter. AQR Capital Management LLC now owns 114,520 shares of the biopharmaceutical company’s stock valued at $604,000 after acquiring an additional 80,908 shares during the last quarter. Institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics is a clinical?stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life?threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non?viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV?based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.